# Oramed

> Mediated Wiki article. Canonical URL: https://mediated.wiki/source/Oramed
> Markdown URL: https://mediated.wiki/source/Oramed.md
> Source: https://en.wikipedia.org/wiki/Oramed
> Source revision: 1309694708
> License: Creative Commons Attribution-ShareAlike 4.0 International (https://creativecommons.org/licenses/by-sa/4.0/)

{{Short description|Pharmaceutical company of Israel}}
{{Use dmy dates|date=July 2023}}

{{Infobox company
| name = Oramed Pharmaceuticals Inc.
| logo = Oramed logo 2022.svg
| caption = 
| trading_name = <!-- d/b/a/, doing business as - if different from legal name above -->
| native_name = <!-- Company's name in home country language -->
| native_name_lang = <!-- Use ISO 639-2 code, e.g. "fr" for French. If there is more than one native name, in different languages, enter those names using {{lang}}, instead. -->
| romanized = 
| former type = 
| type = [Public](/source/Public_company)
| traded_as = {{Nasdaq|ORMP}}<br />[Russell Microcap Index](/source/Russell_Microcap_Index) component
<br/>{{TLV|ORMP}}
| industry = [Biotech](/source/Biotech)
| fate = 
| predecessor = 
| successor = 
| foundation = {{Start date and age|2006}}
| founder = 
| defunct = <!-- {{End date|YYYY|MM|DD}} -->
| location_city = [Jerusalem](/source/Jerusalem)
| location_country = 
| locations = <!-- Number of locations, stores, offices &c. -->
| area_served = 
| key_people = Nadav Kidron ([CEO](/source/Chief_executive_officer))
| products = 
| production = 
| services = 
| revenue = 
| operating_income = 
| net_income = 
| assets = 
| equity = 
| owner = 
| num_employees = 
| parent = 
| divisions = 
| subsid = 
| homepage = {{URL|oramed.com}}
| footnotes = 
| intl = 
| bodystyle = 
}}

'''Oramed Pharmaceuticals Inc.''' ({{Langx|he|אורמד}}), is a publicly traded company engaged in the development of [oral drug delivery](/source/oral_drug) systems – most notably an oral insulin capsule for treating [type 2 diabetes](/source/type_2_diabetes). The company was founded in 2006 and is headquartered in [Jerusalem](/source/Jerusalem). Its shares are listed on the [NASDAQ Capital Market](/source/NASDAQ_Capital_Market) and the Tel Aviv Stock Exchange. 

== History ==
Oramed Pharmaceuticals was founded in 2006 by Miriam Kidron, a scientist at the [Hadassah University Hospital](/source/Hadassah_Medical_Center) in Jerusalem, and her son Nadav Kidron.<ref>{{cite news|last=Weinreb|first=Gali|title=Insulin pill co Oramed jumps on Nasdaq listing plans|url=http://www.globes.co.il/serveen/globes/docview.asp?did=1000814732&fid=1725|accessdate=16 February 2013|newspaper=[Globes](/source/Globes_(newspaper))|date=15 January 2013}}</ref><ref>{{cite web|last=Blackburn|first=Nicky|title=Israeli patent moves closer to achieving oral insulin treatment|url=http://israel21c.org/health/israeli-patent-moves-closer-to-achieving-oral-insulin-treatment/|publisher=Israel21c|accessdate=16 February 2013|date=24 June 2007}}</ref>

== Product pipeline ==
Oramed considers its flagship product to be an oral insulin capsule developed to treat sufferers of [type 2 diabetes](/source/type_2_diabetes). The Company is currently conducting Phase 3 trials, under the FDA, for oral insulin in Type 2 diabetes.  

In addition to the oral insulin capsule, Oramed is developing an [exenatide](/source/exenatide)-based capsule designed to balance blood sugar levels and control appetite, and is conducting clinical trials for the treatment of NASH with oral insulin.<ref>{{Cite web |last=Leichman |first=Abigail Klein |date=2013-02-12 |title=Groundbreaking insulin pill nearing market |url=https://www.israel21c.org/groundbreaking-insulin-pill-nearing-market/ |access-date=2025-05-08 |website=ISRAEL21c |language=en-US}}</ref><ref name=":0" /><ref>{{Cite web |title=Oramed Pharmaceuticals Inc.: An emerging player in the huge orally delivered therapeutics segment of the global diabetes care market; we initiate our coverage with a price target of NIS 53.2 |url=https://mayafiles.tase.co.il/rpdf/1138001-1139000/P1138037-00.pdf |website=mayafiles.tase.co.il}}</ref> 

In 2021, Oramed created a subsidiary, Oravax Medical, to bring an oral Covid-19 vaccine to market.<ref>{{Cite web |date=2021-08-17 |title=Israel developing injectable and oral vaccines as COVID cases soar |url=https://www.mobihealthnews.com/news/emea/israel-developing-injectable-and-oral-vaccines-covid-cases-soar |access-date=2025-05-08 |website=MobiHealthNews |language=en}}</ref><ref>{{Cite web |date=2021-07-22 |title=Israel to become first in world to test Oravax oral COVID-19 vaccine |url=https://www.jpost.com/health-science/israel-to-become-first-in-world-to-test-oral-covid-19-vaccine-674563 |access-date=2025-05-08 |website=[The Jerusalem Post](/source/The_Jerusalem_Post) |language=en |issn=0792-822X}}</ref>

In January 2023, a Phase 3 trial of Oramed's orally administered insulin for Type 2 diabetes patients failed, thus causing the share price to plunge.<ref>{{cite news|url=https://en.globes.co.il/en/article-oramed-plunges-after-reporting-trial-failure-1001435437|title=Oramed plunges after reporting trial failure|publisher=Globes|access-date=4 May 2023}}</ref> The company has mentioned that the pill worked for a subset of the population and will pursue a Phase 3 trial for that subset. <ref name=":0">{{cite news|url=https://www.clinicaltrialsarena.com/news/oramed-diabetes-oral-insulin-pivotal-trial/?cf-view |title=Oramed to reinitiate pivotal type 2 diabetes trial after Phase III flop |website=clinicaltrialsarena.com |date=2024-02-21 |access-date=2025-05-03}}</ref>

In May 2023, [Ben Shapiro](/source/Ben_Shapiro) invested $4.7 million and was named to the board of directors.<ref>{{cite news |last=Serafino |first=Phil |last2=Odenheimer |first2=Alisa |date=2 May 2023 |title=Conservative Pundit Ben Shapiro Invests $4.7 Million in Israeli Drug Company |url=https://www.bloomberg.com/news/articles/2023-05-02/conservative-pundit-shapiro-takes-stake-in-israeli-drug-company?leadSource=uverify%20wall&sref=xhJDrP3t |access-date=4 May 2023 |publisher=Bloomberg}}</ref>

On May 15, 2023, it was reported that Oramed's insulin pill was approved in China and will work with a Chinese firm to apply for marketing authorizations.<ref name=":0" /><ref>{{Cite web |last=Pharmaceuticals |first=Oramed |date=2018-12-13 |title=Oral Insulin Moves Towards Becoming Reality in U.S., China |url=https://www.globaltrademag.com/oral-insulin-moves-towards-becoming-reality-in-u-s-china/ |access-date=2025-05-08 |website=Global Trade Magazine}}</ref> 

== Subsidiaries ==

OraTech Pharmaceuticals is a joint venture formed by Oramed Pharmaceuticals and Hefei Tianhui Biotech, to commercialize its insulin capsule and is expected to list on the NASDAQ sometime in 2025.

== See also ==
*[Avram Hershko](/source/Avram_Hershko)
*[List of companies of Israel](/source/List_of_companies_of_Israel)
*[List of Israeli companies quoted on the Nasdaq](/source/List_of_Israeli_companies_quoted_on_the_Nasdaq)

== References ==
{{Reflist}}

{{Israel NASDAQ}}{{TA 100 companies}}
Category:Biotechnology companies of Israel
Category:Companies listed on the Nasdaq
Category:Pharmaceutical companies of Israel
Category:Pharmaceutical companies established in 2006
Category:2006 establishments in Israel

---
Adapted from the Wikipedia article [Oramed](https://en.wikipedia.org/wiki/Oramed) by Wikipedia contributors ([contributor history](https://en.wikipedia.org/wiki/Oramed?action=history)). Available under [Creative Commons Attribution-ShareAlike 4.0 International](https://creativecommons.org/licenses/by-sa/4.0/). Changes may have been made.